ICE2

Across TCGA pan-cancer cohorts, ICE2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ICE2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ICE2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ICE2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and CCRCC are the cancer types where ICE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	IV	0.507	0.905	.002	23	view →
UCEC	OS	Quartile	All	1.000	0.864	.036	12	view →
CCRCC	OS	Median	III,IV	0.104	0.985	.014	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ICE2–HNSC (DFS)

Open the HNSC breakdown →